The usage of anti-IL2r monoclonal antibodies for induction therapy has reduced the frequency of acute rejection. Up to now there are very rare experiences of this treatment among Iranian patients. This study demonstrates the efficacy of induction therapy with Basiliximab and Daclizumab in kidney transplantation among Iranian patients in Shariati Hospital of Tehran. 43 patients were randomly divided into two groups. 18 patients received Basiliximab as a 20 mg dosage at day 0 of transplantation and then a 20 mg dosage 4 days after the transplantation (Group I) and the other 25 patients received Daclizumab as doses of 1 mg/Kg at day 0 of transplantation and then four further doses in two week intervals after the transplantation (Group II). The last serum creatinine level of the patients was used as the comparison factor between the groups. The data was analyzed by mean of SPSS Software version 13.5. The mean age of the patients was 38.5±15.2 years (44.5±16.8 years in group I vs. 34.4±12.7 years in group II). The mean serum creatinine level was 1.4±0.7 (1.3±0.2 in group I vs. 1.5±0.9 in group II, P>0.05). Out of 43 patients, 25.6% (n=11) were experiencing their second or third kidney transplantation (27.8% in group I vs. 24% in group II). The mean creatinine level was lower in patients who were experiencing their first kidney transplantation (P>0.05). There was an acute rejection rate of 11.6% among the patients (22.2% in group I vs. 4% in group II, P>0.05). Among these 43 patients, 4.7% (n=2) were expired after the transplantation (5.6% in group I vs. 4% in group II, P>0.05). The results of this study showed that the usage of monoclonal antibodies for induction therapy reduces the frequency of acute rejection in kidney transplantation among Iranian patients. There were no significant differences between the results of therapy with Basiliximab and Daclizumab. Future comprehensive studies are needed to reveal more aspects of the benefits of these therapies.